演題速報 デイリーランキング
このサイトは医療関係者の方々を対象に作成しています。
必ずご利用規約に同意の上、ご利用ください。記事内容で取り上げた薬剤の効能・効果および用法・用量には、日本国内で承認されている内容と異なるものが、多分に含まれていますのでご注意ください。
6月4日 演題レポート
Abstract #3535
Final results of study 20050181: A randomized phase III study of FOLFIRI +/- Panitumumab for the 2nd-line treatment of metastatic colorectal cancer
Alberto F. Sobrero, et al.
Abstract #3555
Phase II study of Panitumumab (P) in combination with FOLFOXIRI as first-line treatment of metastatic colorectal cancer (mCRC): High activity in molecularly selected patients (pts)
Sara Lonardi, et al.
Abstract #3557
Post-progression survival according to treatment line, type and time in phase III trials in advanced colorectal cancer
Marc Buyse, et al.
Abstract #3569
Short-term clinical outcomes from a randomized controlled trial to evaluate laparoscopic and open surgery for stage II, III colorectal cancer (CRC): Japan Clinical Oncology Group study JCOG0404 (NCT00147134/ UMIN-CTR: 000000105)
Yusuke Nishizawa, et al.
Abstract #3580
Mechanisms Mediating the Negative Interaction Between Oxaliplatin（Ox） and Epidermal Growth Factor Receptor (EGFR) Inhibitors in Patients with KRAS Mutant (MT) Colorectal Cancer
Daniel J. Freeman, et al.
Abstract #3593
Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab (IRIS/BEV) in patients with metastatic colorectal cancer: Update analysis -Hokkaido Gastrointestinal Cancer Study Group (HGCSG) study
Satoshi Yuki, et al.
Abstract #4010
Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial
Michael Alexander Gordon, et al.
Abstract #4012
ACTS-GC試験に登録された病理学的stage II/III胃癌症例の生存期間に対するインスリン様成長因子1受容体 (IGF1R) とamphiregulin (AREG) の発現が影響に関する解析
Impact of insulin-like growth factor 1 receptor (IGF1R) and amphiregulin (AREG) expression on survival in patients with stage II/III gastric cancer enrolled in the ACTS-GC study
Wataru Ichikawa, et al.
Abstract #4014
Multivariate analysis including biomarkers in the phase III RADIANT-2 study of Octreotide LAR plus Everolimus or placebo among patients with advanced neuroendocrine tumors
Marc Buyse, et al.
Abstract #4031
Randomized phase II trial of Gemcitabine plus S-1 combination therapy versus S-1 in advanced biliary tract cancer: Results of the Japan Clinical Oncology Group study (JCOG0805)
Makoto Ueno, et al.
Multicenter retrospective analysis of systemic chemotherapy in poorly neuroendocrine carcinoma of digestive system
Nozomu Machida, et al.
Abstract #4015
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal poorly differentiated neuroendocrine carcinoma: The NORDIC NEC Study
Halfdan Sorbye, et al.
Abstract #4067
Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer
Kohei Shitara, et al.
Abstract #LBA10008
Randomized phase III trial of Regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least Imatinib (IM) and Sunitinib (SU): The GRID trial
George D. Demetri, et al.